美公共专利基金会要专利商标局复审艾滋病药物专利
2010年08月31日09:34
公共专利基金会(PUBPAT)在新闻稿中宣布,它已正式要求美国专利商标局复审雅培制药公司持有的8项专利,它们与艾滋病毒/艾滋病(HIV/AIDS)的关键药物利托那韦有关,伊利诺伊州芝加哥市制药巨头Norvir正在销售该药物。
在该请求下,PUBPAT提交了曾经意料之外的在先技术,以表明这8项专利不应该获得授权。PUBPAT还引用了最近联邦巡回法院的判例法,以支持这8项专利无效的主张。
受到质疑的美国专利号为:5,541,206、5,635,523、5,648,497、5,674,882、 6,037,157、6,703,403、7,148,359和 7,364,752。这8项有关100毫克利托那韦药品的专利都被列入美国食品及药物管理局(FDA)的橙皮书中,并于2010年2月10日获得批准。
作为一种称为蛋白酶抑制剂,利托那韦由于其抗病毒特性最初被用于艾滋病毒感染和艾滋病抗病毒治疗中,不过,通过抑制分解药物的酶,它现在被更广泛的用于加强其他蛋白酶抑制剂的功效。因此,它仍旧是艾滋病毒/艾滋病治疗的关键药物。
来源:中国保护知识产权网站
- 艾滋病早期治疗是康复与延长30~60年生命的保
- 艾滋病免疫重建的重要意义是挽救生命的根本
- 从食品植物研究开发的治疗艾滋病新药三合皂甙
- 康生丹颗粒免疫实验提示符合艾滋病、肿瘤等应
- 鸡尾酒疗法并非万能,抗药性与毒副作用导致联合疗法与中药疗法应用的迫切性
- 康生丹配合西药治疗AIDS总结
- 三合皂甙,康生丹片
- 中药康生丹治愈艾滋病中医论析
-
-
Public Patent Foundation, the U.S. Patent and Trademark Office to review patents of AIDS drugs
At 09:34 on the August 31, 2010
Public Patent Foundation (PUBPAT) in a press release announced that it has formally asked the U.S. Patent and Trademark Office to review Abbott Laboratories holds 8 patents, and along with HIV / AIDS (HIV / AIDS) key drugs ritonavir Wei relevant, Chicago, Illinois, the pharmaceutical giant is selling the drug Norvir.
In the request, PUBPAT submitted prior art have been unexpected, to indicate that the 8 patents should not be authorized. PUBPAT also cited a recent federal circuit court case law to support the eight patent claims invalid.
Challenged the U.S. patent number: 5,541,206,5,635,523,5,648,497,5,674,882, 6,037,157,6,703,403,7,148,359 and 7,364,752. This 8 for the 100 mm Clito patent medicines ritonavir were included in the U.S. Food and Drug Administration (FDA) of the orange book, and in February 10, 2010 approved.
Known as a protease inhibitor, ritonavir because of its anti-viral properties were first used for HIV infection and AIDS anti-viral therapy, however, decomposition of drugs by inhibiting the enzyme, it is now more widely used to strengthen the effectiveness of other protease inhibitors. Therefore, it is still the HIV / AIDS treatment, the key drugs.
Source: IPR protection website
|